{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:20:00Z","timestamp":1793596800948,"version":"4.5.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe the management of refractory antibody-mediated rejection (AMR) in a highly sensitized lung transplant recipient, emphasizing the use of eculizumab as rescue therapy, and to highlight the importance of continuous monitoring in posttransplant patients and the role of multidisciplinary teams in addressing complex cases of graft rejection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This case report describes a 58-year-old woman with high immunologic risk who underwent bilateral lung transplantation. The patient did not receive pretransplant desensitization. In the early posttransplant period, she developed possible AMR with severe respiratory deterioration and required venovenous extracorporeal membrane oxygenation (ECMO). Initial treatment included corticosteroids, plasmapheresis, intravenous immune globulins, and thymoglobulin. However, donor-specific antibodies levels increased, and the patient\u2019s respiratory condition deteriorated further. Eculizumab was administered as second-line therapy, leading to both clinical and immunological improvement. The patient survived and was eventually discharged from the intensive care unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Eculizumab may represent a viable rescue option in cases of refractory AMR after lung transplantation, including in patients requiring ECMO support. This case highlights the importance of tailored therapeutic strategies and multidisciplinary evaluation in managing high-risk transplant recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf298","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:20:12Z","timestamp":1761744012000},"page":"266-271","source":"Crossref","is-referenced-by-count":3,"title":["Eculizumab as rescue therapy for antibody-mediated rejection in a high-risk lung transplant recipient: A case report"],"prefix":"10.1093","volume":"83","author":[{"given":"Adrian","family":"Puertas Sanjuan","sequence":"first","affiliation":[{"name":"Pharmacy, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Sacanell-Lacasa","sequence":"additional","affiliation":[{"name":"Critical Care Unit, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"G\u00f3mez Domingo","sequence":"additional","affiliation":[{"name":"Pharmacy, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Pau-Parra","sequence":"additional","affiliation":[{"name":"Pharmacy, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Riera del Brio","sequence":"additional","affiliation":[{"name":"Critical Care Unit, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Berastegui","sequence":"additional","affiliation":[{"name":"Lung Transplant Unit, Department of Respiratory Medicine, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina B","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Rosado Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Lalueza Broto","sequence":"additional","affiliation":[{"name":"Pharmacy, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dom\u00e9nech-Moral","sequence":"additional","affiliation":[{"name":"Pharmacy, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2026030907324605400_zxaf298-B1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231213112","article-title":"A complement to traditional treatments for antibody-mediated rejection? Use of eculizumab in lung transplantation: a review and early center experience","author":"Kleiboeker","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2026030907324605400_zxaf298-B2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1513\/pats.200808-080GO","article-title":"Acute rejection and humoral sensitization in lung transplant recipients","volume":"6","author":"Martinu","year":"2009","journal-title":"Proc Am Thorac Soc"},{"issue":"10","key":"2026030907324605400_zxaf298-B3","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.healun.2004.11.049","article-title":"Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition","volume":"24","author":"Christie","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"2026030907324605400_zxaf298-B4","author":"Sacanell"},{"issue":"5","key":"2026030907324605400_zxaf298-B5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2014.01.019","article-title":"Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee","volume":"20","author":"Bubalo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2026030907324605400_zxaf298-B6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.healun.2016.01.1227","article-title":"Antibody-mediated rejection of the lung: a consensus report of the ISHLT","volume":"35","author":"Levine","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2026030907324605400_zxaf298-B7","author":"Eculizumab"},{"issue":"12","key":"2026030907324605400_zxaf298-B8","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1161\/CIR.0000000000000598","article-title":"Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association","volume":"139","author":"Colvin","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"2026030907324605400_zxaf298-B9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.healun.2021.05.019","article-title":"Outcomes of pre- heart transplantation desensitization in a series of highly sensitized patients bridged with left ventricular assist devices","volume":"40","author":"Saadi","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"2026030907324605400_zxaf298-B10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/ajt.13076","article-title":"Survival in sensitized lung transplant recipients with perioperative desensitization","volume":"15","author":"Tinckam","year":"2015","journal-title":"Am J Transplant"},{"issue":"12","key":"2026030907324605400_zxaf298-B11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.healun.2012.09.016","article-title":"Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab","volume":"31","author":"Dawson","year":"2012","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"2026030907324605400_zxaf298-B12","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1097\/TP.0000000000002165","article-title":"Acute antibody-mediated rejection 1 week after lung transplantation successfully treated with eculizumab, intravenous immunoglobulins, and rituximab","volume":"102","author":"Muller","year":"2018","journal-title":"Transplantation"},{"key":"2026030907324605400_zxaf298-B13","doi-asserted-by":"crossref","first-page":"102174","DOI":"10.1016\/j.trim.2025.102174","article-title":"Effectiveness of complement inhibitors against refractory antibody-mediated rejection of lung transplantation: two clinical cases","volume":"89","author":"Mallet","year":"2025","journal-title":"Transpl Immunol"},{"issue":"12","key":"2026030907324605400_zxaf298-B14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"2026030907324605400_zxaf298-B15","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/TP.0000000000002639","article-title":"Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation"},{"issue":"10","key":"2026030907324605400_zxaf298-B16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ajt.15397","article-title":"Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies","volume":"19","author":"Glotz","year":"2019","journal-title":"Am J Transplant"},{"issue":"18","key":"2026030907324605400_zxaf298-B17","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIR.0000000000000093","article-title":"Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association","volume":"131","author":"Colvin","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"2026030907324605400_zxaf298-B18","doi-asserted-by":"crossref","first-page":"e12726","DOI":"10.1111\/xen.12726","article-title":"Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation","volume":"29","author":"Yerly","year":"2022","journal-title":"Xenotransplantation"},{"issue":"8","key":"2026030907324605400_zxaf298-B19","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2026030907324605400_zxaf298-B20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2026030907324605400_zxaf298-B21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf298\/65043633\/zxaf298.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/6\/266\/65043633\/zxaf298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/6\/266\/65043633\/zxaf298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:32:53Z","timestamp":1773055973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/6\/266\/8307011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf298","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,15]]},"published":{"date-parts":[[2025,10,30]]}}}